Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis
Status:
Active, not recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Primary sclerosing cholangitis (PSC) is an idiopathic condition with intrahepatic cholangitis
and fibrosis, leading to multifocal bile duct stricture. Its main clinical manifestations are
chronic cholestatic lesions and is deemed as autoimmune liver disease. PSC are immune
abnormalities that occurs in patients with genetic susceptibility. No other pathogenesis is
revealed yet. Ursodeoxycholic acid is used as an empirical treatment, and there is no
approved drug or a acceptable treatment regimen. The disease often progresses to liver
decompensation and requires liver transplantation. In recent years, the clinical application
of stem cell therapy has seen many important advances. Stem cells are characterized with
properties of multiple differentiation, repair of damaged tissue and immuno-modulation. This
study aims to employ UCMSCs to treat PSC patients and observe its efficacy and safety, and to
explore the possible therapeutic mechanisms.